PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
Open Access
- 3 August 2020
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 39 (1) , 1-15
Abstract
Background: Colorectal cancer (CRC) is one of the most common malignancies, and it’s expected that the CRC burden will substantially increase in the next two decades. New biomarkers for targeted treatment and associated molecular mechanism of tumorigenesis remain to be explored. In this study, we investigated whether PDCD6 plays an oncogenic role in colorectal cancer and its underlying mechanism. Methods: Programmed cell death protein 6 (PDCD6) expression in CRC samples were analyzed by immunohistochemistry and immunofluorescence. The prognosis between PDCD6 and clinical features were analyzed. The roles of PDCD6 in cellular proliferation and tumor growth were measured by using CCK8, colony formation, and tumor xenograft in nude mice. RNA-sequence (RNA-seq), Mass Spectrum (MS), Co-Immunoprecipitation (Co-IP) and Western blot were utilized to investigate the mechanism of tumor progression. Immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR) were performed to determine the correlation of PDCD6 and MAPK pathway. Results: Higher expression levels of PDCD6 in tumor tissues were associated with a poorer prognosis in patients with CRC. Furthermore, PDCD6 increased cell proliferation in vitro and tumor growth in vivo. Mechanistically, RNA-seq showed that PDCD6 could affect the activation of the MAPK signaling pathway. PDCD6 interacted with c-Raf, resulting in the activation of downstream c-Raf/MEK/ERK pathway and the upregulation of core cell proliferation genes such as MYC and JUN. Conclusions: These findings reveal the oncogenic effect of PDCD6 in CRC by activating c-Raf/MEK/ERK pathway and indicate that PDCD6 might be a potential prognostic indicator and therapeutic target for patients with colorectal cancer.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, 2017-I2M-3-009, 2017-12M-4-002)
- National Key Research and Development Program of China (2018YFC1003500)
- National Natural Science Foundation of China (81672472, 81672461, 31725013)
- National Key Basic Research Program of China (2015CB943001)
- State Key Project on Infection Diseases of China (2017ZX10201021-007-003)
- State Key Laboratory Special Fund from the Ministry of Science (2060204)
This publication has 55 references indexed in Scilit:
- Raf kinase inhibitor protein (RKIP) in cancerCancer and Metastasis Reviews, 2012
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated byNRASorMEKMutationsMolecular Cancer Therapeutics, 2012
- PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancerJournal of Translational Medicine, 2012
- ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell deathBiochemical and Biophysical Research Communications, 2009
- The Ca2+-binding Protein ALG-2 Is Recruited to Endoplasmic Reticulum Exit Sites by Sec31A and Stabilizes the Localization of Sec31AMolecular Biology of the Cell, 2006
- Intracellular calcium signalingJournal of Cell Science, 2002
- Apoptosis-Linked Gene 2-Deficient Mice Exhibit Normal T-Cell Development and FunctionMolecular and Cellular Biology, 2002
- ALG-2 Interacts with the Amino-Terminal Domain of Annexin XI in a Ca2+-Dependent MannerBiochemical and Biophysical Research Communications, 2002
- Apoptosis-Linked Gene 2 Binds to the Death Domain of Fas and Dissociates from Fas during Fas-Mediated Apoptosis in Jurkat CellsBiochemical and Biophysical Research Communications, 2001
- Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) proteinCell Death & Differentiation, 1999